Connect with us

Health and Wellness

The latest Covid booster will be available soon. Should I get one? Am I eligible?

Published

on

Australia Therapeutic Goods Administration (TGA) recently approved a brand new booster vaccine against Covid-19. The shot was developed by Pfizer and Targets subvariant JN.1 by Omicron.

This is now the fifth version of the COVID vaccines, that are updated often to maintain up with the rapidly evolving SARS-CoV-2 virus.

But nearly five years into the pandemic, it’s possible you’ll be wondering, why do we’d like one more style of booster vaccine? And will we still must take legal highs in any respect? Here’s what to contemplate.

Targeting the spike protein

JN.1 booster from Pfizer (and Moderna, although TGA has not approved this stage) relies on mRNA technology. This technology instructs our cells to provide a particular protein – on this case, the SARS-CoV-2 spike, a protein on the surface of the virus that permits it to connect to our cells.

This helps the immune system produce antibodies that recognize the spike protein and stop the virus from entering our cells.

In response to our enhanced immune response from vaccinations and former infections (called immune pressure), SARS-CoV-2 has continued to evolve over the course of the pandemic, modifying the form of the spike protein, making our antibodies less effective.

We’ve been coping with a soup of Omicron subvariants recently, including the JN.1. Since the detection of JN.1 in August 2023this subvariant of Omicron spawned many further subvariants akin to KP.2 (referred to as FLiRT), KP.3 (referred to as FLUQE), and XEC.

The spike protein consists of 1273 amino acidstype of like molecular constructing blocks. Mutations to spike protein change individual amino acids.

Certain amino acids are necessary for neutralizing antibodies to bind to the spike protein. This means the changes could give the virus a bonus over earlier variants, helping it evade our immune response.

Scientists are continually updating Covid-19 vaccines, attempting to sustain with these changes. The higher the vaccine’s “spike” matches the spike protein on the surface of the virus trying to contaminate you, the more protection you possibly can get.

So who should get vaccinated and when?

Updating vaccines to combat mutating viruses isn’t a brand new concept. This has since been the case with the flu vaccine around 1950.

We have develop into accustomed to the annual flu vaccine within the run-up to winter cold and flu season. However, unlike the flu, the coronavirus doesn’t follow an annual seasonal cycle. The frequency of waves of Covid-19 infections is variable, with recent waves occurring periodically.

Covid too more portable than the flu, which is one other challenge. Although numbers vary, a conservative estimate of the reproduction number (R0 – how many individuals one person infects) for JN.1 is 5. Compare this to seasonal flu with an R0 of about 1.3. In other words, COVID may be 4 times more contagious than the flu.

Add to this the immunity resulting from vaccination against Covid (or previous infection) begins to weaken in the next months.

Therefore, for some more vulnerable people, an annual Covid-19 booster isn’t considered sufficient.

For adults aged 65 to 74a booster dose is beneficial every 12 months, but every six months is eligible. For adults over 75, a shot is beneficial every six months.

Adults aged 18 to 64 are eligible every 12 months unless they’ve a severe immune deficiency. Immunodeficiency could cause many conditions, including genetic disorders, infections, cancer, autoimmune diseases, diabetes and lung diseases, in addition to organ transplantation. For this group, they’re beneficial to receive the shot every 12 months, but are eligible every six.

Regular Covid-19 boosters are beneficial for people who find themselves over 65 years of age or who’re prone to underlying health conditions.
Production AYO/Shutterstock

Understanding the recommendation

The JN.1-targeted vaccine should provide good protection against Omicron virus subvariants which might be more likely to be in circulation in the approaching months.

There are a couple of things that must occur before JN.1 vaccines are available, akin to the Australian Technical Advisory Group on Immunization providing guidance to the federal government. However, we are able to reasonably expect that they will be implemented inside the subsequent month.

If they reach doctors’ offices and pharmacies before Christmas and you plan to make use of a booster dose, the vacation period may be a further incentive to purchase it, especially in case you plan to attend many family and social gatherings in the summertime.

In the meantime, XBB.1.5 vaccines remain available. While these are targeted against the sooner Omicron subvariant, they need to still provide some protection.

While young, healthy people should want to wait for updated booster doses, for many who are vulnerable and require vaccination, the choice to carry off on vaccination may be something to contemplate along with your doctor.

Australia’s COVID booster vaccine recommendations, with stronger wording (“recommended” relatively than “eligible”) used for vulnerable groups, reflect what we learn about Covid-19. People who’re older and medically vulnerable usually tend to develop into very unwell as a result of the virus.

For young, healthy individuals who may be wondering, “Do I even need a COVID booster vaccine?”, it is sensible to get one yearly. Although you’re less more likely to get Covid, it is feasible. Importantly, vaccines also reduce risk developing long Covid.

While COVID vaccines are superb at protecting against severe disease, they don’t necessarily prevent infection. Evidence that they reduce transmission has been mixedAND has modified over time.

We realized that vaccination will not free us from Covid-19. But it remains to be our greatest defense against severe disease.

This article was originally published on : theconversation.com
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Health and Wellness

Jury awarded $310 million to parents of teenager who died after falling on a ride at Florida amusement park – Essence

Published

on

By

Sun Sentinel/Getty Images

The family of Tire Sampson, the 14-yr-old who tragically died on an amusement park ride in Orlando, Florida, in 2022, has been awarded $310 million in a civil lawsuit.

Tire, who was visiting ICON Park along with his family on March 24, 2022, fell from the FreeFall drop tower. Although he was taken to a nearby hospital, he didn’t survive his injuries.

Now, greater than two years later, a jury has held the vehicle manufacturer, Austria-based Funtime Handels, responsible for the accident and awarded the Tire family $310 million. According to reports from local news stations WFTV AND KSDKthe jury reached its verdict after about an hour of deliberation.

Tyre’s parents will each receive $155 million, according to attorney spokesman Michael Haggard.

Attorneys Ben Crump and Natalie Jackson, who represented Tyre’s family, shared their thoughts on this landmark decision via X (formerly Twitter). “This ruling is a step forward in holding corporations accountable for the safety of their products,” they said in a statement.

Lawyers stressed that Tyre’s death was attributable to “gross negligence and a failure to put safety before profits.” They added that the ride’s manufacturer had “neglected its duty to protect passengers” and that the substantial award ensured it could “face the consequences of its decisions.”

Crump and Jackson said they hope the result will encourage change throughout the theme park industry. “We hope this will spur the entire industry to enforce more stringent safety measures,” they said. “Tire heritage will provide a safer future for drivers around the world.”

An investigation previously found that Tyre’s harness was locked through the descent, but he dislodged from his seat through the 430-foot fall when the magnets engaged. Tire’s death was ruled the result of “multiple injuries and trauma.”

ICON Park said at the time that it could “fully cooperate” with the authorities.

This article was originally published on : www.essence.com
Continue Reading

Health and Wellness

Tireless HIV/AIDS advocate A. Cornelius Baker dies

Published

on

By

HIV/AIDS Advocate, A. Cornelius Baker


A. Cornelius Baker, a tireless advocate of HIV and AIDS testing, research and vaccination, died Nov. 8 at his home in Washington, D.C., of hypertensive, atherosclerotic heart problems, in response to his partner, Gregory Nevins.

As previously reported, Baker was an early supporter for people living with HIV and AIDS within the Nineteen Eighties, when misinformation and fear-mongering in regards to the disease were rampant.

According to Douglas M. Brooks, director of the Office of National AIDS Policy under President Obama, it was Baker’s Christian faith that guided him toward compassion for others.

“He was very kind, very warm and inclusive – his circles, both professional and personal, were the most diverse I have ever seen, and he was guided by his Christian values,” Brooks told the outlet. “His ferocity was on display when people were marginalized, rejected or forgotten.”

In 1995, when he was executive director of the National AIDS Association, Baker pushed for June 27 to be designated National HIV Testing Day.

In 2012, he later wrote on the web site of the Global Health Advisor for which he was a technical advisor that: “These efforts were intended to help reduce the stigma associated with HIV testing and normalize it as part of regular screening.”

https://twitter.com/NBJContheMove/status/1856725113967632663?s=19

Baker also feared that men like himself, black gay men, and other men from marginalized communities were disproportionately affected by HIV and AIDS.

Baker pressured the Clinton administration to incorporate black and Latino people in clinical drug trials, and in 1994 he pointedly told the Clinton administration that he was bored with hearing guarantees but seeing no motion.

According to Lambda Legal CEO Kevin Jennings, yes that daring attitude that defines Baker’s legacy in the world of ​​HIV/AIDS promotion.

“Cornelius was a legendary leader in the fight for equality for LGBTQ+ people and all people living with HIV,” Jennings said in a press release. “In the more than twenty years that I knew him, I was continually impressed not only by how effective he was as a leader, but also by how he managed to strike the balance between being fierce and kind at the same time. His loss is devastating.”

Jennings continued: “Cornelius’ leadership can’t be overstated. For many years, he was one in all the nation’s leading HIV/AIDS warriors, working locally, nationally and internationally. No matter where he went, he proudly supported the HIV/AIDS community from the Nineteen Eighties until his death, serving in various positions including the Department of Health and Human Services, the National Association of Persons with Disabilities AIDS, and the Whitman-Walker Clinic . Jennings explained.

Jennings concluded: “His career also included several honors, including being the first recipient of the American Foundation for AIDS Research Foundation’s organization-building Courage Award. Our communities have lost a pillar in Cornelius, and as we mourn his death, we will be forever grateful for his decades of service to the community.”

Kaye Hayes, deputy assistant secretary for communicable diseases and director of the Office of Infectious Diseases and HIV/AIDS Policy, in her comment about his legacy, she called Baker “the North Star.”.

“It is difficult to overstate the impact his loss had on public health, the HIV/AIDS community or the place he held in my heart personally,” Hayes told Hiv.gov. “He was pushing us, charging us, pulling us, pushing us. With his unwavering commitment to the HIV movement, he represented the north star, constructing coalitions across sectors and dealing with leaders across the political spectrum to deal with health disparities and advocate for access to HIV treatment and look after all. He said, “The work isn’t done, the charge is still there, move on – you know what you have to do.” It’s in my ear and in my heart in the case of this job.

Hayes added: “His death is a significant loss to the public health community and to the many others who benefited from Cornelius’ vigilance. His legacy will continue to inspire and motivate us all.”

Baker is survived by his mother, Shirley Baker; his partner Nevins, who can be senior counsel at Lambda Legal; his sisters Chandrika Baker, Nadine Wallace and Yavodka Bishop; in addition to his two brothers, Kareem and Roosevelt Dowdell; along with the larger HIV/AIDS advocacy community.


This article was originally published on : www.blackenterprise.com
Continue Reading

Health and Wellness

Bovaer is added to cow feed to reduce methane emissions. Does it pass into milk and meat? And is it harmful to humans?

Published

on

By

There are growing concerns in regards to the use of feed supplements, Bowar 10to reduce methane production in cows.

Bovaer 10 consists of silicon dioxide (mainly sand), propylene glycol (food stabilizer approved by Food Safety Australia New Zealand) and lively substance 3-nitrooxypropanol (3-NOP).

There has been an enormous amount of misinformation in regards to the safety of 3-NOP, with some milk from herds fed this additive being labeled “Frankenmilk”. Others feared it could get to humans through beef.

The most significant thing is that 3-NOP is secure. Let’s clear up some major misconceptions.

Why do we want to limit methane production?

In our attempts to limit global warming, we’ve placed the best emphasis on CO₂ because the major man-made greenhouse gas. But methane is also a greenhouse gas, and although we produce less of it, it is: a much stronger greenhouse gas than CO₂.

Agriculture is the largest a man-made source of methane. As cattle herds expand to meet our growing demand for meat and milk, reducing methane production from cows is a vital way to reduce greenhouse gas emissions.

There are several ways to do that. Stopping bacteria within the stomachs of cows that produce methane one approach is to produce methane.

The methane produced by cows and sheep doesn’t come from the animals themselves, but from the microbes living of their digestive systems. 3-NO stop the enzymes that perform the last step of methane synthesis in these microorganisms.

3-NOP is not the one compound tested as a feed additive. Australian product based on seaweed, Rumin8for instance, it is also in development. Saponins, soap-like chemicals present in plants, and essential oils as well has been examined.

However, 3-NOP is currently one of the popular effective treatments.

Nitrooxypropanol structure: red balls are oxygen, gray carbon, blue nitrogen and white hydrogen.
PubChem

But is not it poison?

There are concerns on social media that Bovaer is “poisoning our food.”

But, as we are saying in toxicology, it’s the dose that makes the poison. For example, arsenic is deadly 2–20 milligrams per kilogram of body weight.

In contrast, 3-NOP was not lethal on the doses utilized in safety studies, up to 600 mg 3-NOP per kg body weight. At a dose of 100 mg per kg body weight in rats, it didn’t cause any adversarial effects.

What about reproductive issues?

The effect of 3-NOP on the reproductive organs has generated numerous commentary.

Studies in rats and cows showed that doses of 300–500 mg per kg body weight caused: contraction of the ovaries and testicles.

In comparison, to achieve the identical exposure in humans, a 70 kg human would want to eat 21–35 grams (about 2 tablespoons) of pure 3-NOP every day for a lot of weeks to see this effect.

No human will likely be exposed to this amount because 3-NOP doesn’t pass into milk – is fully metabolized within the cow’s intestines.

No cow will likely be exposed to these levels either.

The cow licks itself
Cows will not be exposed to levels tested on animals in laboratory studies.
Ground photo/Shutterstock

What about cancer?

3-NOP is not genotoxic or mutagenicwhich implies it cannot damage DNA. Thus, the results of 3-NOP are dose-limited, meaning that small doses will not be harmful, while very high doses are (unlike radiation where there is no secure dose).

Scientists found that at a dose of 300 mg per kilogram of body weight benign tumors of the small intestine of female ratsbut not male rats, after 2 years of every day consumption. At a dose of 100 mg 3-NOP per kg body weight, no tumors were observed.

Cows eat lower than 2 grams of Bovaer 10 per day (of which only 10% or 0.2 grams is 3-NOP). This is about 1,000 times lower than the appropriate every day intake 1 mg 3-NOP per kg body weight per day for a cow weighing 450 kg.

This level of consumption will likely be not the result in cancer or any of them other adversarial effects.

So how much are people exposed to?

Milk and meat consumers will likely be exposed to zero 3-NOP. 3-NOP doesn’t penetrate milk and meat: is completely metabolized within the cow’s intestines.

Farmers could also be exposed to small amounts of the feed additive, and industrial employees producing 3-NOP will potentially be exposed to larger amounts. Farmers and industrial employees already wear personal protective equipment to reduce exposure to other agricultural chemicals – and it is advisable to do that with Bovear 10 as well.

Milk
3-NOP doesn’t penetrate milk and meat.
Shutterstock

How widely has it been tested?

3-NOP has been in development for 15 years and has been subject to multiple reviews by European Food Safety Authority, UK Food Safety Authority AND others.

It has been extensively tested over months of exposure to cattle and has produced no unintended effects. Some studies actually say so improves the standard of milk and meat.

Bovaer was approved for use in dairy cattle by the European Union from 2022 and Japan in 2024. It is also utilized in many other countries, including: in beef products, amongst others Australia.

A really small amount of 3-NOP enters the environment (lower than 0.2% of the dose taken), no accumulates and is easily decomposed subsequently, it doesn’t pose a threat to the environment.

Since humans will not be exposed to 3-NOP through milk and meat, long-term exposure is not an issue.

What does Bill Gates have to do with this?

Bill Gates has invested in a distinct feed processing method for methane, Australian seaweed-based Rumin8. But he has nothing to do with Bovaer 10.

The Bill & Melinda Gates Foundation awarded research grants to the corporate producing 3-NOP for malaria control researchnot for 3-NOP.

The bottom line is that adding 3-NOP to animal feed doesn’t pose any risk to consumers, animals or the environment.

This article was originally published on : theconversation.com
Continue Reading
Advertisement

OUR NEWSLETTER

Subscribe Us To Receive Our Latest News Directly In Your Inbox!

We don’t spam! Read our privacy policy for more info.

Trending